Emma Pang

Emma Pang is a partner with AllBright and mainly works at the Shanghai office.

Emma’s primary practice areas include cross-border investments, cross-border technology transfer, banking, commercial disputes resolution, and general corporate matters. Emma has assisted many international companies in entering China via greenfield investment or mergers and acquisitions; she also assisted many Chinese companies, including several listed companies, in the process of “Going-out.” Emma’s serves for the inbound and outbound investments range from project searching, selection of locations, negotiations on term sheets, transaction structuring, transaction documents draft, project negotiation, and closing-related matters. In cross-border technology transfer, Emma advised clean-tech and life science companies in technologies licensing, providing services including negotiation of term sheets, structuring transaction and draft, and negotiating the license agreement. Emma has deep knowledge of banking-related matters, advising many banks and non-bank financial institutions on such matters as bank facilities, financial products, trust products, fund products, and other businesses. She is experienced in complex commercial litigations and arbitrations, having represented clients in many types of cases, including bill frauds, loans, share transfer, asset managements, and international trade disputes.

Before joining Allbright, Emma worked in a well-known American law firm for seven years.

Representative Cases:

Cross-Border Transactions
Represented Shanghai Maling in acquiring Silver Fern Farms (transaction amount: RMB 1 billion)
Represented Baogang Metal in selling majority interests to Warburg Pincus and establishing a joint venture (transaction amount: RMB 4 billion)
Represented Chinese investors in the restructuring of Shen-Mei Beverage & Food Co., Ltd. for Coca-Cola bottling operations

Cross-Border Technology Transfer
Represented Flux Drive (Changzhou) Co., Ltd. in licensing in clean technologies from a U.S. company
Represented Autobio Diagnostics (603658) in licensing in molecular diagnostics technologies
Represented Frontier Biosciences (688221) in licensing in PCSK-9 vaccine

Litigation and Arbitration
Represented Heng Feng Bank in wining an over RMB 700 million judgment against Tianshen Entertainment Company
Represented ADM in a corn international trade dispute in CIETA

Publications
Mainland Further Liberalizes Investment Restrictions for Hong Kong Investors under the New CEPA Agreement
Commentary on the Draft of the Implementing Regulations of the Foreign Investment Law
It's Hard to Be a Competent Cross-Border M&A Lawyer Without Accounting Knowledge
How to Understand "Securities" under U.S. Securities Law: Analysis of SEC v. Kik Canada ICO Case
Analysis of the Effect of Choice of Law Clause in GAFTA Model Contract
How Chinese Enterprises Respond to Arbitration by Foreign Arbitral Institutions from the Perspective of Chinese Law
A Study of Civil Jurisprudence on Private Equity Fund Disputes under the Crossover of Civil and Criminal Law
Judicial Empirical Analysis of the Differential Top-up Repurchase Arrangement under M&A Fund Structure – A Study on the Announcements of Listed Companies
The Impact of the Legal Rules of Concealment on Financing Dispute Cases from the Perspective of the Jiu-Min Minutes
A Concise Analysis of Cases on Setting Aside and Non-enforcement of Commercial Arbitration Awards (published by China Law Press in October 2020)

Social Services
Arbitrator, Shanghai Arbitration Commission
External mentor for graduate students, the East China University of Political Science and Law